|Bid||99.06 x 1100|
|Ask||99.48 x 800|
|Day's range||92.97 - 104.18|
|52-week range||16.87 - 127.19|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||N/A|
|Earnings date||25 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||137.11|
Natera and Personalis Partner for Personalized Monitoring in Oncology
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. Co-Diagnostics (NASDAQ: CODX), Aspira Women's Health (NASDAQ: AWH), Fulgent Genetics (NASDAQ: FLGT), GenMark Diagnostics (NASDAQ: GNMK), and Natera (NASDAQ: NTRA) were the five best-performing diagnostics companies last year among those with a market cap above $200 million.